Pre-Market Buzz: Vertex Pharmaceuticals (VRTX), Orexigen Therapeutics (OREX), Fibrocell Science (FCSC), Star Bulk Carriers (SBLK)

Shares of Vertex Pharmaceuticals Inc (VRTX) are higher by 7.18% to $132.99 in pre-market trading on Wednesday after the company’s cystic fibrosis treatment Orkambi won the backing of FDA Advisory Panel which voted 12 to 1 to recommend approval of the drug. The Food and Drug Administration is expected to make a decision on the […] View the full post at: Pre-Market Buzz: Vertex Pharmaceuticals (VRTX), Orexigen Therapeutics (OREX), Fibrocell Science (FCSC), Star Bulk Carriers (SBLK) Related posts: Zhongsheng Pulls Hong Kong IPO In Sign of Market Weakness Experimental Prostate-Cancer Drug Shows Promise The Washington Office-Space Market is in its Toughest Stretch Ever